Researchers argue that the rate of development of drugs (and of some vaccines and diagnostics) would increase if more incentives were created using patent rights and providing guarantees to purchase drugs for the poor as they are developed.
The report (The New Landscape of Neglected Disease Drug Development) by Mary Moran and colleagues at the Pharmaceutical Research and Development Policy Group, The George Institute, argues that drugs for neglected diseases are increasingly being developed partly due to the use of public-private partnership (PPPs) mechanisms that spread the financial and organisational risk of product development. Anne-Laure Ropars, from the George Institute will be discussing the rise of drug development for neglected diseases and the role of PPPs at a major international conference, organised by the ESRC Innogen Centre to be held in London on 5-6 September 2006.
Steven Matlin, Executive Director of the Global Forum for Health Research, also speaking at the conference, does not believe that the increases in development of health products for neglected diseases (drugs, vaccines and diagnostics) is simply due to the rise of PPPs. Matlin also stresses the rise of a group of ‘innovating developing countries’ (IDCs) including Brazil, China, India and South Africa. He argues that these countries have “growing national capacity for high-quality manufacturing to convert the inventions into health products for both domestic and international markets.”
Matlin does acknowledge the challenges faced by both PPPs and IDCs in developing health products for neglected diseases. The third speaker in this conference session, Robert Eiss, Executive Director of the Centre for the Management of Intellectual Property in Health Research, tackles these challenges in more depth. Eiss believes that correct market incentives and, in particular, appropriate intellectual property management are lacking. Eiss states that there is a “need to develop and promote forms of intellectual property management and technology transfer practice that help ensure access for the poor through the strategic use of such tools as price tiering and market segmentation, and the engagement of R&D and manufacturing capacities in countries where the targeted disease is endemic.”
Ropars, Matlin and Eiss will speak about drugs for neglected diseases during the session ‘Health Partnerships and Action” to be held at the ESRC Innogen conference on Wednesday 6th September 2006 at 14.00hrs.
Annika Howard | alfa
Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin
Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy